Meta-Analyses of 8 Polymorphisms Associated with the Risk of the Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Xu, Xuting ^a   Wang, Yunliang ^b   Wang, Lingyan ^c   Liao, Qi ^a   Chang, Lan ^a   Xu, Leiting ^a   Huang, Yi ^a   Ye, Huadan ^a   Xu, Limin ^a   Chen, Cheng ^a   Shen, Xiaowei ^a   Zhang, Fuqiang ^d   Ye, Meng ^a   Wang, Qinwen ^a   Duan, Shiwei ^a  

^a NINGBO UNIVERSITY   (China)

^b The Neurology Department of the 148th Hospital of PLA   (China)

^c NINGBO NO 2 HOSPITAL   (China)

^d Ningbo Institute of Microcirculation and Henbane   (China)

Author keywords

[No Author keywords available]

Indexed keywords

A2M GENE; ABCA2 GENE; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHAT GENE; COMT GENE; DNA POLYMORPHISM; ETHNIC GROUP; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HTR6 GENE; HUMAN; ITALIAN; LPL GENE; NORTHERN AMERICAN; POPULATION RESEARCH; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84883762189     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073129     Document Type: Article

References (76)

1. Vina J, Lloret A, (2010) Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 20Suppl 2: S527-533.
2. Molsa PK, Marttila RJ, Rinne UK, (1986) Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 74: 103-107.
3. Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP, (2005) [The economical impact of dementia]. Presse Med 34: 35-41.
4. Meek PD, McKeithan K, Schumock GT (1998) Economic considerations in Alzheimer's disease. Pharmacotherapy 18: 68-73; discussion 79-82.
5. Francis PT, Palmer AM, Snape M, Wilcock GK, (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147.
6. Hardy J, Allsop D, (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388.
7. Mudher A, Lovestone S, (2002) Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25: 22-26.
8. Mubumbila V, Sutter A, Ptok U, Heun R, Quirin-Stricker C, (2002) Identification of a single nucleotide polymorphism in the choline acetyltransferase gene associated with Alzheimer's disease. Neurosci Lett 333: 9-12.
9. Kooi EJ, Prins M, Bajic N, Belien JA, Gerritsen WH, et al. (2011) Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 122: 313-322.
10. Mengel-From J, Christensen K, Thinggaard M, McGue M, Christiansen L, (2011) Genetic variants in the choline acetyltransferase (ChAT) gene are modestly associated with normal cognitive function in the elderly. Genes Brain Behav 10: 876-882.
11. Orlacchio A, Kawarai T, Paciotti E, Stefani A, Sorbi S, et al. (2002) Association study of the 5-hydroxytryptamine(6) receptor gene in Alzheimer's disease. Neurosci Lett 325: 13-16.
12. Guldberg HC, Marsden CA, (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27: 135-206.
13. Gennatas ED, Cholfin JA, Zhou J, Crawford RK, Sasaki DA, et al. (2012) COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures. Neurology 78: 1663-1669.
14. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, et al. (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19: 357-360.
15. Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, et al. (1998) Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A 95: 3275-3280.
16. Narita M, Holtzman DM, Schwartz AL, Bu G, (1997) Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem 69: 1904-1911.
17. Herring A, Yasin H, Ambree O, Sachser N, Paulus W, et al. (2008) Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol 18: 32-39.
18. Jin M, Shepardson N, Yang T, Chen G, Walsh D, et al. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108: 5819-5824.
19. Haass C, Kaether C, Thinakaran G, Sisodia S, (2012) Trafficking and Proteolytic Processing of APP. Cold Spring Harb Perspect Med 2: a006270.
20. Lambert MP, Sabo S, Zhang C, Enam SA, Klein WL, (1995) Constitutive Alzheimer's-type tau epitopes in a neuritogenic rat CNS cell line. Neurobiol Aging 16: 583-589.
21. Kaminski WE, Piehler A, Pullmann K, Porsch-Ozcurumez M, Duong C, et al. (2001) Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 281: 249-258.
22. Chen ZJ, Vulevic B, Ile KE, Soulika A, Davis W Jr, et al. (2004) Association of ABCA2 expression with determinants of Alzheimer's disease. FASEB J 18: 1129-1131.
23. Nunez M, Peinado-Onsurbe J, Vilaro S, Llobera M, (1995) Lipoprotein lipase activity in developing rat brain areas. Biol Neonate 68: 119-127.
24. Ben-Zeev O, Doolittle MH, Singh N, Chang CH, Schotz MC, (1990) Synthesis and regulation of lipoprotein lipase in the hippocampus. J Lipid Res 31: 1307-1313.
25. Lee JJ, Jo SA, Park JH, Lee SB, Jo I, et al. (2012) Choline acetyltransferase 2384G >a polymorphism and the risk of Alzheimer disease. Alzheimer Dis Assoc Disord 26: 81-87.
26. Harold D, Peirce T, Moskvina V, Myers A, Jones S, et al. (2003) Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet 113: 258-267.
27. Mace S, Cousin E, Ricard S, Genin E, Spanakis E, et al. (2005) ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol Dis 18: 119-125.
28. Depboylu C, Lohmuller F, Du Y, Riemenschneider M, Kurz A, et al. (2006) Alpha2-macroglobulin, lipoprotein receptor-related protein and lipoprotein receptor-associated protein and the genetic risk for developing Alzheimer's disease. Neurosci Lett 400: 187-190.
29. Chen D, Zhang JW, Zhang ZX, Wu YN, Qu QM, (2004) Association of alpha 2-macroglobulin polymorphisms and Alzheimer disease in Mainland Han Chinese. J Neurol Sci 217: 13-15.
30. Jhoo JH, Kim KW, Lee DY, Lee KU, Lee JH, et al. (2001) Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans. J Neurol Sci 184: 21-25.
31. Ki CS, Na DL, Kim HJ, Kim JW, (2001) Alpha-1 antichymotrypsin and alpha-2 macroglobulin gene polymorphisms are not associated with Korean late-onset Alzheimer's disease. Neurosci Lett 302: 69-72.
32. Camelo D, Arboleda G, Yunis JJ, Pardo R, Arango G, et al. (2004) Angiotensin-converting enzyme and alpha-2-macroglobulin gene polymorphisms are not associated with Alzheimer's disease in Colombian patients. J Neurol Sci 218: 47-51.
33. Clarimon J, Bertranpetit J, Calafell F, Boada M, Tarraga L, et al. (2003) Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population. Psychiatr Genet 13: 85-90.
34. Zappia M, Cittadella R, Manna I, Nicoletti G, Andreoli V, et al. (2002) Genetic association of alpha2-macroglobulin polymorphisms with AD in southern Italy. Neurology 59: 756-758.
35. Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, et al. (2001) Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet 9: 437-444.
36. Bagli M, Papassotiropoulos A, Jessen F, Schmitz S, Rao ML, et al. (2000) Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. Am J Med Genet 96: 775-777.
37. Styczynska M, Religa D, Pfeffer A, Luczywek E, Wasiak B, et al. (2003) Simultaneous analysis of five genetic risk factors in Polish patients with Alzheimer's disease. Neurosci Lett 344: 99-102.
38. Zappia M, Manna I, Serra P, Cittadella R, Andreoli V, et al. (2004) Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch Neurol 61: 341-344.
39. Mariani E, Seripa D, Ingegni T, Nocentini G, Mangialasche F, et al. (2006) Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. J Neurol Sci 247: 187-191.
40. Bruno E, Quattrocchi G, Nicoletti A, Le Pira F, Maci T, et al. (2010) Lack of interaction between LRP1 and A2M polymorphisms for the risk of Alzheimer disease. Neurosci Lett 482: 112-116.
41. Minster RL, DeKosky ST, Kamboh MI, (2009) No association of DAPK1 and ABCA2 SNPs on chromosome 9 with Alzheimer's disease. Neurobiol Aging 30: 1890-1891.
42. Wollmer MA, Kapaki E, Hersberger M, Muntwyler J, Brunner F, et al. (2006) Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 141B: 534-536.
43. Ozturk A, DeKosky ST, Kamboh MI, (2006) Genetic variation in the choline acetyltransferase (CHAT) gene may be associated with the risk of Alzheimer's disease. Neurobiol Aging 27: 1440-1444.
44. Grunblatt E, Reif A, Jungwirth S, Galimberti D, Weber H, et al. (2011) Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: the VITA and Milano studies. J Psychiatr Res 45: 1250-1256.
45. Ahn Jo S, Ahn K, Kim JH, Kang BH, Kim E, et al. (2006) ApoE-epsilon 4-dependent association of the choline acetyltransferase gene polymorphisms (2384G >A and 1882G >A) with Alzheimer's disease. Clin Chim Acta 368: 179-182.
46. Forero DA, Benitez B, Arboleda G, Yunis JJ, Pardo R, et al. (2006) Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia. Neurosci Res 55: 334-341.
47. Martinez MF, Martin XE, Alcelay LG, Flores JC, Valiente JM, et al. (2009) The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci 10: 125.
48. Lanni C, Garbin G, Lisa A, Biundo F, Ranzenigo A, et al. (2012) Influence of COMT Val158Met Polymorphism on Alzheimer's Disease and Mild Cognitive Impairment in Italian Patients. J Alzheimers Dis.
49. Thornton V, Warden D, Talbot C, Mastana SS, Bandelow S, et al. (2011) Modification of estrogen's association with Alzheimer's disease risk by genetic polymorphisms. Brain Res 1379: 213-223.
50. Thome J, Retz W, Baader M, Pesold B, Hu M, et al. (2001) Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease. J Neural Transm 108: 1175-1180.
51. Alvarez-Alvarez M, Galdos L, Fernandez-Martinez M, Gomez-Busto F, Garcia-Centeno V, et al. (2003) 5-Hydroxytryptamine 6 receptor (5-HT(6)) receptor and apolipoprotein E (ApoE) polymorphisms in patients with Alzheimer's disease in the Basque Country. Neurosci Lett 339: 85-87.
52. Kan R, Wang B, Zhang C, Yang Z, Ji S, et al. (2004) Association of the HTR6 polymorphism C267T with late-onset Alzheimer's disease in Chinese. Neurosci Lett 372: 27-29.
53. Fidani L, Compton D, Hardy J, Petersen RC, Tangalos E, et al. (2002) No association between the lipoprotein lipase S447X polymorphism and Alzheimer's disease. Neurosci Lett 322: 192-194.
54. Baum L, Wiebusch H, Pang CP, (2000) Roles for lipoprotein lipase in Alzheimer's disease: an association study. Microsc Res Tech 50: 291-296.
55. Martin-Rehrmann MD, Cho HS, Rebeck GW, (2002) Lack of association of two lipoprotein lipase polymorphisms with Alzheimer's disease. Neurosci Lett 328: 109-112.
56. Baum L, Chen L, Masliah E, Chan YS, Ng HK, et al. (1999) Lipoprotein lipase mutations and Alzheimer's disease. Am J Med Genet 88: 136-139.
57. Zill P, Burger K, Behrens S, Hampel H, Padberg F, et al. (2000) Polymorphisms in the alpha-2 macroglobulin gene in psychogeriatric patients. Neurosci Lett 294: 69-72.
58. Estrela C, Silva JA, de Alencar AH, Leles CR, Decurcio DA, (2008) Efficacy of sodium hypochlorite and chlorhexidine against Enterococcus faecalis-a systematic review. J Appl Oral Sci 16: 364-368.
59. Coory MD (2010) Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 39: 932; author reply 933.
60. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, et al. (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106: 1159-1166.
61. Mettenburg JM, Webb DJ, Gonias SL, (2002) Distinct binding sites in the structure of alpha 2-macroglobulin mediate the interaction with beta-amyloid peptide and growth factors. J Biol Chem 277: 13338-13345.
62. Smith JD, Le Goff W, Settle M, Brubaker G, Waelde C, et al. (2004) ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res 45: 635-644.
63. Davis W Jr, (2011) The ATP-binding cassette transporter-2 (ABCA2) regulates cholesterol homeostasis and low-density lipoprotein receptor metabolism in N2a neuroblastoma cells. Biochim Biophys Acta 1811: 1152-1164.
64. Ricciarelli R, Canepa E, Marengo B, Marinari UM, Poli G, et al. (2012) Cholesterol and Alzheimer's disease: a still poorly understood correlation. IUBMB Life 64: 931-935.
65. Davis W Jr, (2010) The ATP-binding cassette transporter-2 (ABCA2) increases endogenous amyloid precursor protein expression and Abeta fragment generation. Curr Alzheimer Res 7: 566-577.
66. Oda Y, (1999) Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 49: 921-937.
67. Gil-Bea FJ, Garcia-Alloza M, Dominguez J, Marcos B, Ramirez MJ, (2005) Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit. Neurosci Lett 375: 37-41.
68. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, et al. (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64: 749-760.
69. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, et al. (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51: 145-155.
70. Wilcock GK, Esiri MM, Bowen DM, Smith CC, (1982) Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 57: 407-417.
71. Kanju PM, Parameshwaran K, Sims-Robinson C, Uthayathas S, Josephson EM, et al. (2012) Selective cholinergic depletion in medial septum leads to impaired long term potentiation and glutamatergic synaptic currents in the hippocampus. PLoS One 7: e31073.
72. Nunes-Tavares N, Santos LE, Stutz B, Brito-Moreira J, Klein WL, et al. (2012) Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-beta peptide oligomers. J Biol Chem 287: 19377-19385.
73. Nishitsuji K, Hosono T, Uchimura K, Michikawa M, (2011) Lipoprotein lipase is a novel amyloid beta (Abeta)-binding protein that promotes glycosaminoglycan-dependent cellular uptake of Abeta in astrocytes. J Biol Chem 286: 6393-6401.
74. Xie C, Wang ZC, Liu XF, Yang MS, (2010) The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. Eur J Hum Genet 18: 3-7.
75. Papassotiropoulos A, Wollmer MA, Tsolaki M, Brunner F, Molyva D, et al. (2005) A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J Clin Psychiatry 66: 940-947.
76. Paradis E, Clement S, Julien P, Ven Murthy MR, (2003) Lipoprotein lipase affects the survival and differentiation of neural cells exposed to very low density lipoprotein. J Biol Chem 278: 9698-9705.